MX2020001547A - Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. - Google Patents

Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Info

Publication number
MX2020001547A
MX2020001547A MX2020001547A MX2020001547A MX2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A MX 2020001547 A MX2020001547 A MX 2020001547A
Authority
MX
Mexico
Prior art keywords
fluorobenzofuran
indol
dione
methyl
solid forms
Prior art date
Application number
MX2020001547A
Other languages
English (en)
Spanish (es)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020001547(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2020001547A publication Critical patent/MX2020001547A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
MX2020001547A 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. MX2020001547A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
MX2020001547A true MX2020001547A (es) 2020-08-03

Family

ID=63405430

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020001547A MX2020001547A (es) 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2024003249A MX2024003249A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2024003249A MX2024003249A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Country Status (16)

Country Link
US (3) US11136334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3665176B1 (cg-RX-API-DMAC7.html)
JP (3) JP7424639B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250070131A (cg-RX-API-DMAC7.html)
CN (2) CN117362305A (cg-RX-API-DMAC7.html)
AU (3) AU2018313259B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002892A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072240A1 (cg-RX-API-DMAC7.html)
DK (1) DK3665176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974328T3 (cg-RX-API-DMAC7.html)
FI (1) FI3665176T3 (cg-RX-API-DMAC7.html)
IL (2) IL272556B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020001547A (cg-RX-API-DMAC7.html)
PL (1) PL3665176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3665176T (cg-RX-API-DMAC7.html)
WO (1) WO2019032958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
CA3251821A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. ORAL DOSAGE FORMS OF ELRAGLUSIB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2013515737A (ja) 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法

Also Published As

Publication number Publication date
DK3665176T3 (da) 2024-03-25
WO2019032958A1 (en) 2019-02-14
US11136334B2 (en) 2021-10-05
US20200223861A1 (en) 2020-07-16
KR20250070131A (ko) 2025-05-20
PT3665176T (pt) 2024-03-13
IL272556A (en) 2020-03-31
US20220009939A1 (en) 2022-01-13
MX2024003249A (es) 2024-04-04
CN111247153A (zh) 2020-06-05
JP2026012715A (ja) 2026-01-27
CA3072240A1 (en) 2019-02-14
IL313800A (en) 2024-08-01
US20250115616A1 (en) 2025-04-10
EP3665176A1 (en) 2020-06-17
MX2023005875A (es) 2023-06-05
AU2023201059A1 (en) 2023-03-23
KR20240063198A (ko) 2024-05-09
ES2974328T3 (es) 2024-06-26
EP3665176B1 (en) 2024-01-24
CN111247153B (zh) 2024-04-02
IL272556B2 (en) 2025-01-01
BR112020002892A2 (pt) 2020-08-04
JP2020530497A (ja) 2020-10-22
AU2025202936A1 (en) 2025-05-15
CN117362305A (zh) 2024-01-09
JP2023156372A (ja) 2023-10-24
JP7424639B2 (ja) 2024-01-30
JP7778750B2 (ja) 2025-12-02
AU2018313259B2 (en) 2022-11-24
AU2018313259A1 (en) 2020-02-27
AU2023201059B2 (en) 2025-04-03
PL3665176T3 (pl) 2024-06-17
US12145943B2 (en) 2024-11-19
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
KR102700883B1 (ko) 2024-09-02
IL272556B1 (en) 2024-09-01

Similar Documents

Publication Publication Date Title
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
EP4276114A3 (en) Cd20 binding single domain antibodies
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
CO2018008444A2 (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
EP4272832A3 (en) Antimicrobial compounds, compositions, and uses thereof
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
CL2018001911A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
EP4574832A3 (en) Dantrolene prodrugs and methods of their use
MX2024003249A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
CL2008002545A1 (es) Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor.
EP4221704A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES
ES3064009T3 (en) Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
UY30046A1 (es) Nuevos derivados de furopirimidina acíclicos sustitiudos y su uso
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
EP3603656A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PROPHYLACTIC OR THERAPEUTIC TREATMENT OF GYNECOLOGICAL DISEASES CONTAINING SARCODON IMBRICATUS EXTRACT AS ACTIVE INGREDIENT
MX2020004105A (es) Formulacion farmaceutica.
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
CL2008001819A1 (es) Compuestos derivados de fenoxi-fluorobenceno sustituido; composicion farmaceutica; y uso en el tratamiento de enfermedades virales tales como vih y sida.